Dexcom EVP Sells 1,700 Shares Under 10b5-1 Plan

DEXCOM INC executive Michael Jon Brown, EVP Chief Legal Compliance Officer, reported an open-market sale of 1,700 shares of Dexcom common stock on July 15, 2026 at an average price of $74.42 per share, executed under a 10b5-1 plan adopted on November 26, 2025.

Rhea-AI Filing Summary

DEXCOM INC executive Michael Jon Brown, EVP Chief Legal Compliance Officer, reported an open-market sale of 1,700 shares of Dexcom common stock on July 15, 2026 at an average price of $74.42 per share, executed under a 10b5-1 plan adopted on November 26, 2025. Following this transaction, he holds 104,653 shares in total, including 74,753 unvested restricted stock units scheduled to vest in several grants through March 8, 2029.

Insider Trade Summary 10b5-1

Net Seller: 1,700 shares

Net Sell 1 txn

Insider Brown Michael Jon

Role EVP Chief Legal Compliance Off

Sold 1,700 shs ($127K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	1,700	$74.42	$127K

Holdings After Transaction: Common Stock — 104,653 shares (Direct)

Footnotes (2)

1. F1. On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
2. F2. Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Key Figures

Shares Sold: 1,700 shares Sale Price: $74.42 per share Shares Owned After: 104,653 shares +5 more

8 metrics

Shares Sold 1,700 shares Open-market sale of Dexcom common stock on July 15, 2026

Sale Price $74.42 per share Average price for the 1,700 shares sold on July 15, 2026

Shares Owned After 104,653 shares Total beneficial ownership following the reported sale

Unvested RSUs 74,753 units Unvested restricted stock units included in post-transaction holdings

2026 RSU Grant 39,019 units RSUs granted March 8, 2026 vesting through March 8, 2029

2025 RSU Grants 19,948 and 8,549 units RSUs granted March 8, 2025 vesting through March 8, 2028 and March 8, 2027

2024 RSU Grant 7,237 units RSUs granted March 8, 2024 vesting through March 8, 2027

10b5-1 Plan Adoption Date November 26, 2025 Date Michael Jon Brown adopted the 10b5-1 Plan used for this sale

Key Terms

10b5-1 Plan, restricted stock units, vest

3 terms

10b5-1 Plan financial

"On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan."

A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.

restricted stock units financial

"Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vest financial

"39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dexcom (DXCM) report for Michael Jon Brown?

Dexcom reported that EVP Chief Legal Compliance Officer Michael Jon Brown sold 1,700 shares of common stock in an open-market transaction at an average price of $74.42 per share, with the trade dated July 15, 2026 and reported on a Form 4 filing.

At what price and on what date were the DXCM shares sold by Michael Jon Brown?

Michael Jon Brown sold 1,700 Dexcom shares on July 15, 2026 at an average price of $74.42 per share. The transaction is classified as an open-market sale of common stock and was disclosed in his Form 4 insider filing.

How many Dexcom (DXCM) shares does Michael Jon Brown own after this Form 4 sale?

After the sale, Michael Jon Brown beneficially owns 104,653 Dexcom shares. This amount includes 74,753 unvested restricted stock units that are scheduled to vest over time, along with other already vested or owned common shares reported in the Form 4.

Was the Dexcom (DXCM) stock sale by Michael Jon Brown made under a 10b5-1 plan?

Yes. A footnote states that on November 26, 2025, Michael Jon Brown adopted a 10b5-1 Plan permitting orderly disposition of his shares. The 1,700 shares reported sold on July 15, 2026 were executed pursuant to this 10b5-1 plan arrangement.

What restricted stock units (RSUs) are included in Michael Jon Brown's Dexcom (DXCM) holdings?

His post-transaction holdings include 74,753 unvested RSUs: 39,019 granted March 8, 2026 vesting through March 8, 2029; 19,948 and 8,549 granted March 8, 2025 vesting through 2028 and 2027; and 7,237 granted March 8, 2024 vesting through March 8, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/16/2026 - 05:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brown Michael Jon

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Chief Legal Compliance Off

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		S		1,700(1)	D	$74.42	104,653(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan.

2. Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Michael Jon Brown	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)